Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02079064 |
Recruitment Status :
Completed
First Posted : March 5, 2014
Last Update Posted : October 11, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Status; Splenectomy | Drug: Desflurane Drug: Propofol | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis. |
Study Start Date : | January 2014 |
Actual Primary Completion Date : | June 2017 |
Actual Study Completion Date : | July 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Desflurane
Desflurane at 1 MAC and
|
Drug: Desflurane
Inhalational anesthetic
Other Name: Suprane |
Experimental: propofol
propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
|
Drug: Propofol
Intravenous anesthetic that can be given by continuous infusion
Other Name: Diprivan |
- maximum clot firmness (MCF) [ Time Frame: Up to 1 month ]Ultimate strength and stability of the fibrin clot measured by ROTEM.
- clotting time CT [ Time Frame: Up to 1 month ]The time until initial fibrin formation measured by ROTEM
- clot formation time; CFT [ Time Frame: Up to 1 month ]The kinetics of fibrin formation and clot development measured by ROTEM
- D dimer [ Time Frame: Up to 1 month ]Indication of coagulation and fibrinolysis
- Platelet count [ Time Frame: Up to 1 month ]Ability of clot formation
- Prothrombin Time [ Time Frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation ]measures of the extrinsic pathway of coagulation
- International Normalized Ratio (INR) [ Time Frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation ]measures of the extrinsic pathway of coagulation
- sP-selectin [ Time Frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation ]Acts as a receptor that supports binding of leukocytes to activated platelets and endothelium.
- Fibrinogen Level [ Time Frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation ]A soluble plasma glycoprotein, that is converted by thrombin into fibrin during blood clot formation
- D-Dimer [ Time Frame: Pre-operative, after ligation of splenic artery, immediate post-operative, 24 hours and three days after operation ]A fibrin degradation product (or FDP) present in the blood after a blood clot is degraded by fibrinolysis

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient ASA physical status II and III.
- Age between 22-55 years.
- Child A suffering from pancytopenia.
- Type of surgery: splenectomy
Exclusion Criteria:
- Patients using oral anticoagulants
- Patients using antithrombotic drugs
- Patients using non steroidal anti-inflammatory drugs
- Patients using oral contraceptives
- Age less than 25 or more than 55 years
- Obese patients (body mass index >35 kg m-2)
- Pregnancy and lactation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02079064
Egypt | |
Theodor Bilharz Research Institute | |
Giza, Egypt, 12411 |
Study Chair: | Gehan G El-Fandy, M.D. | Theodor Bilharz Research Institute |
Publications of Results:
Responsible Party: | Yasser Mostafa Samhan, Professor of Anesthesia, Theodor Bilharz Research Institute |
ClinicalTrials.gov Identifier: | NCT02079064 |
Other Study ID Numbers: |
Anesthesia 98T |
First Posted: | March 5, 2014 Key Record Dates |
Last Update Posted: | October 11, 2017 |
Last Verified: | October 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Splenectomy Desflurane Propofol TCI ROTEM |
Propofol Desflurane Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs |
Anesthetics, Intravenous Anesthetics, General Anesthetics Anesthetics, Inhalation |